Elutia (NASDAQ:ELUT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Elutia (NASDAQ:ELUT) issued its quarterly earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02), FiscalAI reports. The firm had revenue of $3.11 million during the quarter, compared to the consensus estimate of $3.00 million.

Here are the key takeaways from Elutia’s conference call:

• Elutia said its FDA review of NXT-41 is progressing well, giving management increased confidence in the planned NXT-41X submission and expected timeline of NXT-41 clearance in Q4 2026 and NXT-41X in the first half of 2027.
• The company brought its automated manufacturing platform online during the quarter, and believes it can support 80%+ gross margins at scale while helping keep pricing competitive.
• Management reiterated the large opportunity in breast reconstruction, citing a $1.5 billion U.S. market with high infection rates and limited innovation in current standard of care. They said surgeon feedback supports a concentrated commercial launch focused on a few hundred high-volume hospitals.
• Elutia ended the quarter with $36.5 million in cash and escrow, which management believes is sufficient to fund planned regulatory and operational milestones.
• The company remains active on strategic transactions, including the previously announced SimpliDerm divestiture and newly disclosed inbound interest in its cardiovascular product line, both of which could further strengthen the balance sheet and sharpen focus on NXT-41X.

Elutia Stock Down 1.0%

Shares of ELUT stock opened at $1.03 on Friday. The firm has a market capitalization of $44.06 million, a P/E ratio of 1.20 and a beta of 0.75. Elutia has a twelve month low of $0.50 and a twelve month high of $2.64. The stock’s fifty day simple moving average is $1.09 and its 200 day simple moving average is $0.92.

Analyst Ratings Changes

Several brokerages have recently issued reports on ELUT. Wall Street Zen upgraded Elutia from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Weiss Ratings upgraded Elutia from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, April 10th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Elutia presently has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Institutional Investors Weigh In On Elutia

Hedge funds and other institutional investors have recently bought and sold shares of the company. Deerfield Management Company L.P. bought a new stake in Elutia during the 3rd quarter worth $1,221,000. XTX Topco Ltd bought a new stake in Elutia during the 4th quarter worth $71,000. Renaissance Technologies LLC grew its position in Elutia by 64.7% during the 4th quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock worth $71,000 after acquiring an additional 40,123 shares during the last quarter. Citadel Advisors LLC acquired a new position in Elutia during the 3rd quarter worth about $50,000. Finally, Jane Street Group LLC acquired a new position in Elutia during the 1st quarter worth approximately $48,000. Institutional investors own 74.03% of the company’s stock.

About Elutia

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.